Nutra Pharma Expands Licensing Agreement to Include
Environmental Testing for Nontuberculous Mycobacterium
BOCA RATON, Fla., Dec 27, 2007 (BUSINESS WIRE) -- Nutra Pharma
Corp. (OTCBB:NPHC), a biotechnology company that is developing
drugs for HIV and Multiple Sclerosis (MS), has today announced
that it has expanded its licensing agreement with NanoLogix,
Inc. (Pink Sheets: NNLX) to include intellectual property for
the use of testing the environment for NonTuberculous
Mycobacterium (NTM).
"NTM infections are becoming a major concern for hospitals and
medical clinics around the world", explained Rik J. Deitsch,
Chairman and CEO of Nutra Pharma Corporation. "Combining
our newly licensed intellectual property with our current test
kit technology will allow our subsidiary, Designer Diagnostics,
to attempt to successfully launch a cost-effective solution to
help identify the environmental sources of NTM infections," he
added.
NonTuberculous Mycobacterium, also known as atypical
Tuberculosis (Atypical TB) or Mycobacterium other than
Tuberculosis (MOTT), is a bacteria that is found in water,
including hot tubs and showers, some domestic and wild animals,
and soil. One of the most common forms of NTM infections
found in humans is Mycobacterium avium complex (MAC). This
is a primary cause of respiratory disease in humans and is a
leading cause of death in HIV/AIDS patients.
"Expanding this licensing agreement to include environmental
testing is a natural progression of our relationship with Nutra
Pharma and our belief in its ability to successfully bring these
kits to market, " comments Bret Barnhizer, President and CEO of
NanoLogix, Inc. "In addition to helping detect NTM in
patients, Nutra Pharma will not be able to test for NTM in the
environment to help prevent others from becoming infected," he
concluded.
Nutra Pharma's wholly-owned medical devices subsidiary, Designer
Diagnostics, is currently planning to undergo third party
validation for its NTM diagnostic test kits at leading
Tuberculosis research institute, National Jewish Medical and
Research Center, in Denver, Colorado. The Company plans to
apply for FDA approval upon successful completion of this
clinical trial.
Recently, distinguished NTM research scientist, Dr. Rahul Narang,
used the Designer Diagnostics test kits to test soil and water
samples collected from the environment of patients with NTM
infections. This was the first time the technique was used
in India and the findings were presented in November at the 38th
Union World Conference on Lung Health in Cape Town, South
Africa.
About Nutra Pharma Corp,
Nutra Pharma Corp. is a biopharmaceutical company specializing in the
acquisition, licensing and commercialization of pharmaceutical products
and technologies for the management of neurological disorders, cancer,
autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries
carries out basic drug discovery research and clinical development and also
seeks strategic licensing partnerships to reduce the risks associated with the
drug development process. The Company's holding, ReceptoPharm, Inc, is developing
these technologies for the production of drugs for HIV and Multiple Sclerosis
("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the
research and development of diagnostic test kits designed to be used for the
rapid identification of infectious diseases such as Tuberculosis (TB) and
Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify
and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.DesignerDiagnostics.com
SEC Disclaimer
This press release contains forward-looking statements. The words or
phrases "would be," "will allow," "intends to,"
"will likely result," "are expected to," "will continue," "is
anticipated," "estimate," "project," or similar expressions are
intended to identify "forward-looking statements." Actual results
could differ materially from those projected in Nutra Pharma's
("the Company") business plan. The Company's business is subject
to various risks, which are discussed in the Company's filings with
the Securities and Exchange Commission ("SEC"). The expanded
licensing agreement with NanoLogix, Inc., to include environmental
testing should not be construed as an indication in any way
whatsoever of the value of the Company or its common stock.
The Company's filings may be accessed at the SEC's Edgar system
at www.sec.gov. Statements made herein are as of the date of this
press release and should not be relied upon as of any subsequent
date. The Company cautions readers not to place reliance on such
statements. Unless otherwise required by applicable law, we do not
undertake, and we specifically disclaim any obligation, to update
any forward-looking statements to reflect occurrences, developments,
unanticipated events or circumstances after the date of such statement.
Source:
Nutra Pharma Corp
Contact:
David Isserman
877-895-5647
ir@nutrapharma.com
________________________________________
Contact:
NanoLogix, Inc.
Investor Relations
Bret Barnhizer, CEO
Telephone: 330-534-0800
E-mail:
Bret@nanologixinc.com
